<DOC>
	<DOCNO>NCT00319787</DOCNO>
	<brief_summary>The purpose study determine addition ZD1839 Iressa™ standard treatment Casodex® ( bicalutamide ) locally advanced prostate cancer detect difference rate decrease prostate specific antigen ( PSA ) level .</brief_summary>
	<brief_title>Combination Casodex® Iressa™ Locally Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>18 80 year age . Men histologically confirm locally advanced prostatic adenocarcinoma No prior treatment prostate cancer , include surgery , radiotherapy , cryotherapy thermotherapy . No abnormal laboratory value . No coexist malignancy significant clinical disorder laboratory finding .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>